Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2022 | $10.00 → $5.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/10/2022 | Buy → Neutral | BTIG Research | |
| 8/10/2022 | $12.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 3/2/2022 | Outperform | Cowen | |
| 2/25/2022 | $20.00 → $14.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $36.00 → $20.00 | Equal-Weight | Morgan Stanley |
| 1/6/2022 | $61.00 → $12.00 | Buy → Hold | Stifel |
| 1/6/2022 | Outperform → Mkt Perform | William Blair |
15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)
POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)
S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading
EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi
4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)
4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)
4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)
Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously
BTIG Research downgraded Berkeley Lights from Buy to Neutral
JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously